Literature DB >> 16961575

A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity.

H Hof1.   

Abstract

Posaconazole, a new triazole antifungal, exerts principally the same mechanism of action as the other azole derivatives, i.e. it inhibits the ergosterol production by binding and inhibiting the lanosterol-14alpha-demethylase which is present in almost all fungi except Pneumocystis and Pythium. Posaconazole has an exquisitely high affinity to this target. Since posaconazole has a chemical structure different from fluconazole and voriconazole, it can interact with an additional domain of the target so that it may inhibit even mutated strains resistant to fluconazole and voriconazole. In addition posaconazole is a bad substrate for efflux pumps in fungi, so it can stay active when other azoles are already inactive. Furthermore, the spectrum of posaconazole is rather large including also some zygomycetes resistant to other azoles. In conclusion, posaconazole is actually the most potent azole derivative used in medicine. A combination of posaconazole with other groups of antifungals may have a favourable effect. There are several methods to test the in vitro activities of posaconazole including the E-test, though interpretive breakpoints are still lacking.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16961575     DOI: 10.1111/j.1439-0507.2006.01295.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  28 in total

1.  The Growing Problem of Antifungal Resistance in Onychomycosis and Other Superficial Mycoses.

Authors:  Aditya K Gupta; Helen J Renaud; Emma M Quinlan; Neil H Shear; Vincent Piguet
Journal:  Am J Clin Dermatol       Date:  2020-12-22       Impact factor: 7.403

2.  Refractory Hypokalemia from Syndrome of Apparent Mineralocorticoid Excess on Low-Dose Posaconazole.

Authors:  Travis Wassermann; Eleanor K Reimer; Marie McKinnon; Wendy Stock
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

3.  HSAF-induced antifungal effects in Candida albicans through ROS-mediated apoptosis.

Authors:  Yanjiao Ding; Zhenyu Li; Yaoyao Li; Chunhua Lu; Haoxin Wang; Yuemao Shen; Liangcheng Du
Journal:  RSC Adv       Date:  2016-03-21       Impact factor: 3.361

4.  In vitro Post-Antifungal Effect of Posaconazole and Its Impact on Adhesion-Related Traits and Hemolysin Production of Oral Candida dubliniensis Isolates.

Authors:  Arjuna Nishantha Bandara Ellepola; Ranil Samantha Dassanayake; Ziauddin Khan
Journal:  Med Princ Pract       Date:  2019-06-28       Impact factor: 1.927

Review 5.  Posaconazole : a review of its use in the prophylaxis of invasive fungal infections.

Authors:  James E Frampton; Lesley J Scott
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 6.  Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections.

Authors:  Emily Zoller; Connie Valente; Kyle Baker; Michael E Klepser
Journal:  Drug Des Devel Ther       Date:  2010-11-04       Impact factor: 4.162

Review 7.  Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.

Authors:  Chris Stockmann; Jonathan E Constance; Jessica K Roberts; Jared Olson; Elizabeth H Doby; Krow Ampofo; Justin Stiers; Michael G Spigarelli; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2014-05       Impact factor: 6.447

8.  Potency and Preclinical Evidence of Synergy of Oral Azole Drugs and Miltefosine in an Ex Vivo Model of Leishmania (Viannia) panamensis Infection.

Authors:  Olga Lucía Fernández; Mariana Rosales-Chilama; Natali Quintero; Bruno L Travi; Dawn M Wetzel; María Adelaida Gómez; Nancy Gore Saravia
Journal:  Antimicrob Agents Chemother       Date:  2021-10-25       Impact factor: 5.938

9.  Genomic analysis of the basal lineage fungus Rhizopus oryzae reveals a whole-genome duplication.

Authors:  Li-Jun Ma; Ashraf S Ibrahim; Christopher Skory; Manfred G Grabherr; Gertraud Burger; Margi Butler; Marek Elias; Alexander Idnurm; B Franz Lang; Teruo Sone; Ayumi Abe; Sarah E Calvo; Luis M Corrochano; Reinhard Engels; Jianmin Fu; Wilhelm Hansberg; Jung-Mi Kim; Chinnappa D Kodira; Michael J Koehrsen; Bo Liu; Diego Miranda-Saavedra; Sinead O'Leary; Lucila Ortiz-Castellanos; Russell Poulter; Julio Rodriguez-Romero; José Ruiz-Herrera; Yao-Qing Shen; Qiandong Zeng; James Galagan; Bruce W Birren; Christina A Cuomo; Brian L Wickes
Journal:  PLoS Genet       Date:  2009-07-03       Impact factor: 5.917

10.  Posaconazole in the management of refractory invasive fungal infections.

Authors:  Stefan Langner; Philipp B Staber; Peter Neumeister
Journal:  Ther Clin Risk Manag       Date:  2008-08       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.